FDA Determines Regulatory Review Period for RYDAPT Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its determination of the regulatory review period for RYDAPT, a human drug product, in accordance with federal regulations and in response to patent extension applications submitted to the U.S. Patent and Trademark Office (USPTO).